C83.398, Diffuse large B-cell lymphoma of other extranodal and solid organ sitesICD-10-CM
No Prior Auth Required
Covered without prior authorization (high confidence)
CGS-J15-L34356, Erythropoiesis Stimulating Agents (ESA)
J15
CGS-J15-L38822, MolDX: Minimal Residual Disease Testing for Cancer
J15
CGS-J15-L36021, MolDX: Molecular Diagnostic Tests (MDT)
J15
CGS-J15-L34037, Flow Cytometry
J15
CGS-J15-L40386, Erythropoiesis Stimulating Agents (ESA)
J15
CGS-J18-L34037, Flow Cytometry
J18
CGS-J18-L38822, MolDX: Minimal Residual Disease Testing for Cancer
J18
CGS-J18-L34356, Erythropoiesis Stimulating Agents (ESA)
J18
CGS-J18-L36021, MolDX: Molecular Diagnostic Tests (MDT)
J18
CGS-J18-L40386, Erythropoiesis Stimulating Agents (ESA)
J18
A59259, Billing and Coding: Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin
J5
A58756, Billing and Coding: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer
J5
WPS-J5-L39477, Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin
J5
A59004, Billing and Coding: MolDX: Minimal Residual Disease Testing for Hematologic Cancers
J5
WPS-J5-L38835, MolDX: Minimal Residual Disease Testing for Cancer
J5
WPS-J5-L39040, MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer
J5
A55147, Billing and Coding: MolDX: bioTheranostics Cancer TYPE ID Update
J5
WPS-J5-L36807, MolDX: Molecular Diagnostic Tests (MDT)
J5
NGS-J6-L39297, Off-label Use of Rituximab and Rituximab Biosimilars
J6
NGS-J6-L36850, Peripheral Nerve Blocks
J6
Ask Backwork about documentation requirements, denial risks, or coverage in your state.